This is an exploratory experiment, aims to explore the effective and safety of thalidomide in
the treatment of NTDT to improve the hemoglobin level, improve the quality of life, reduce
blood transfusion, so as to avoid the adverse reactions caused by transfusion.15~30 patients
will be enrolled, including type α 5~13 cases, type β 10~17 cases.